Prospective clinical trial for evaluate the efficacy and safety of traditional Chinese medicine granules in treating chronic obstructive pulmonary disease

Status

Active, not recruiting

Phases

Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR1800020460

Enrollment

Unknown

Registered

2018-12-30

Start date

2019-02-01

Completion date

Unknown

Last updated

2019-01-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

Group 1:Traditional Chinese Medicine Formula Granules + Basic Treatment of Western Medicine

Group 2:Traditional Chinese Medicine Decoction + Basic Treatment of Western Medicine

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Patients who meet the diagnostic criteria of COPD; 2. Patients with mild, moderate and severe acute exacerbation; 3. Age 40 to 75 years; 4. Voluntary treatment and informed consent.

Exclusion criteria

Exclusion criteria: 1. The severity of the disease belongs to patients with stable COPD and extremely severe acute exacerbation. 2. Pregnant and lactating women; 3. Mental disorders, dementia and various psychiatric patients; 4. Cardiac function grade IV and hemodynamic instability; 5. Patients with bronchiectasis, bronchial asthma, active pulmonary tuberculosis, bronchiolitis obliterans, diffuse panbronchiolitis, pulmonary embolism, pneumothorax and pleural effusion; 6. Neuromuscular diseases affecting respiratory and motor functions; 7. Concomitant tumors; 8. Severe liver and kidney diseases (severe liver diseases refer to bleeding from cirrhosis, portal hypertension and varicose veins, and severe kidney diseases include dialysis and kidney transplantation); 9. Long-term bedridden persons for various reasons; 10. Oral administration of glucocorticoids within one month before admission; 11. congenital or acquired immunodeficiency; 12. Those who are participating in clinical trials of other drugs are known to be allergic to the treatment of drug allergies; 13. Participating other clinical study within one month before enrollment.

Design outcomes

Primary

Measure	Time frame
Clinical symptoms and signs;Evaluation of TCM Syndrome;Quality of life;Biochemical indexes;	—

Countries

China

Contacts

Public ContactZegeng Li

The First Affiliated Hospital of Anhui University of Chinese Medicine

li6609@126.com+86 13805516609

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026